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ABSTRACT
The use of cationic liposomes as nonviral vehicles for the delivery of therapeutic molecules is becoming in-
creasingly prevalent in the field of gene therapy. We have previously demonstrated that the use of the trans-
ferrin ligand (Tf) to target a cationic liposome delivery system resulted in a significant increase in the trans-
fection efficiency of the complex [Xu, L., Pirollo, K.F., and Chang, E.H. (1997). Hum. Gene Ther. 8, 467–475].
Delivery of wild-type (wt) p53 to a radiation-resistant squamous cell carcinoma of the head and neck 
(SCCHN) cell line via this ligand-targeted, liposome complex was also able to revert the radiation resistant
phenotype of these cells in vitro. Here we optimized the Tf/liposome/DNA ratio of the complex (LipT) for max-
imum tumor cell targeting, even in the presence of serum. The efficient reestablishment of wtp53 function in
these SCCHN tumor cells in vitro, via the LipT complex, restored the apoptotic pathway, resulting in a sig-
nificant increase in radiation-induced apoptosis that was directly proportional to the level of exogenous wtp53
in the tumor cells. More significantly, intravenous administration of LipT–p53 markedly sensitized established
SCCHN nude mouse xenograft tumors to radiotherapy. The combination of systemic LipT–p53 gene therapy
and radiation resulted in complete tumor regression and inhibition of their recurrence even 6 months after
the end of all treatment. These results indicate that this tumor-specific, ligand–liposome delivery system for
p53 gene therapy, when used in concert with conventional radiotherapy, can provide a new and more effec-
tive means of cancer treatment.
2941
OVERVIEW SUMMARY
A transferrin–cationic liposome system was optimized for
efficient and tumor-specif ic gene delivery both in vitro and
in vivo . The replacement of wild-type p53 by lipT–p53 re-
stored the wtp53 function and apoptotic pathway. The sys-
temic delivery of the LipT–p53 to established nude mouse
xenograft model of human squamous cell carcinoma of the
head and neck markedly sensitized the tumor to radiation
therapy. The combination of system ic p53 gene therapy and
conventional radiotherapy resulted in tumor regression and
inhibition of their recurrence long-term. This strategy may
provide a more effective treatment modality for human
head and neck cancer.
INTRODUCTION
W ILD-TY PE (wt) p53 plays a crucial role in apoptotic path-ways leading to cell death (reviewed in Bates and Vous-
den, 1999). The lack of functional p53 is believed to contribute
to the failure of many cancers to respond to conventional ther-
apies (reviewed by Ruley, 1996; Roth, 1998). For example, the
presence of mutant (mt) p53 has been shown to correlate with
increased radiation resistance in some human tumors and cell
lines, possibly because of the loss of the p53-dependent apop-
totic pathway (Lee and Bernstein, 1993; O’Connor et al., 1993;
McIlwrath et al., 1994; Bristow et al., 1996; Nielson and
Maneval, 1998; Meng and El-Deiry, 1999). Therefore, reestab-
lishing wt p53 function in tumor cells may restore the p53-me-
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diated apoptotic pathway, resulting in more efficient treatment
modalities.
Progress has been made toward developing nonviral, phar-
maceutical formulations of genes for in vivo human therapy,
particularly cationic liposome-med iated gene transfer systems
(Felgner et al., 1995; Templeton et al., 1997; Huang and Vi-
roonchatapan, 1999). However, liposomal systems in general
suffer from low transfection efficiencies when compared with
those observed with viral vector delivery systems. The trans-
fection efficiency of cationic liposom es can be dramatically in-
creased when a ligand recognizing a cell surface receptor is in-
cluded in the complex. The presence of the ligand facilitates
the entry of the DNA–liposome complex into the cell through
the initial binding of ligand by its receptor on the cell surface,
followed by internalization of the bound complex via receptor-
mediated endocytosis (Cheng, 1996), a highly efficient inter-
nalization pathway present in eukaryotic cells (Christiano and
Curiel, 1996; Wagner, 1999). We have previously reported that
the addition of the transferrin (Tf) ligand to a cationic liposome
complex resulted in an in vitro transfection efficiency of
70–80% in squamous cell carcinoma of the head and neck 
(SCCHN) as compared with only 5–20% transfection by the
cationic liposome complex without Tf (L. Xu et al., 1997).
Transferrin receptor (TfR) levels are known to be elevated in
various types of cancer cells including breast (Inoue et al., 1993)
and prostate cancers (Keer et al., 1990), even those prostate
cancer cell lines derived from human lymph node and bone
metastases (Grayhack et al., 1979; Chackal-Roy et al., 1989;
Rossi and Zetter, 1992), as well as squam ous cell carcinomas
(Thorstensen and Romsio, 1993; Miyamoto et al., 1994), and
correlate with the aggressive or proliferative ability of tumor
cells (Elliott et al., 1993).
Squamous cell carcinoma of the head and neck is one of the
most difficult forms of cancer to treat successfully. Approxi-
mately 40,000 new cases are diagnosed in the United States
each year, with more than 12,000 individuals succumbing to
this devastating disease annually (Landis et al., 1998). Despite
advances in the preferred forms of therapy, i.e., surgery and ra-
diation, and now even chemotherapy, no major improvement
in efficacy and survival has occurred over the past several
decades. Approximately  70% of patients with advanced disease
(stage III–IV) will still die from their illness, primarily from re-
current disease, which occurs in more than 60% of patients
(Dimery and Hong, 1993). Even 25% of those with early stage
disease (stage I–II) are incurable (van Dongen and Snow, 1997).
Resistance to ionizing radiation by a subset of the tumor cells
is believed to account for a significant portion of these clinical
failures. Therefore, a new treatm ent modality that results in sen-
sitization of these tumors to standard radiation therapy would
have a marked effect on the clinical outcome of this disease for
many patients.
In our previous report (L. Xu et al., 1997), we demonstrated
that wt p53 was efficiently delivered to SCCHN tumor cells in
vitro by the Tf–liposome complex. The high-level expression
of this exogenous wt p53 in the Tf–liposome–DNA-transfected
cells resulted in the reversion of the radioresistant phenotype
of the SCCHN cells in a DNA dose-dependent manner. In the
present study, we further optimized the transferrin– cationic li-
posome system for systemic p53 gene therapy of SCCHN and
demonstrate that the transduced wt p53 restored wt p53 func-
tion in these cells, leading to increased radiation-induced apop-
tosis in a p53 DNA-dependent manner. These findings indicate
that the reversal of the radiation resistance of the SCCHN cells
observed in vitro in our previous report was due to this restora-
tion of the p53-dependent apoptotic pathway.
Most significantly, we examined the ability of transfected wt
p53 to sensitize SCCHN to radiation in vivo . Our findings
demonstrate that this transferrin– cationic liposome system
could preferentially deliver the p53 gene to preestablished 
SCCHN xenograft tumors and sensitize them to radiotherapy,
resulting in long-term tumor regression in animals receiving the
combination therapy. This sensitization of SCCHN tumors,
through the combination of systemic p53 gene therapy and ion-
izing irradiation, has the potential for use as a new therapeutic
modality for the treatment not only of initial malignancies, but
also for the larger challenge of recurrent disease.
MATERIALS AND METHODS
Cell culture
Human head and neck cell line JSQ-3, derived from a tumor
of the nasal vestibule that failed radiotherapy, was a generous
gift from R. Weichselbaum  (University of Chicago; Weichsel-
baum et al., 1993). The cell line was maintained in minimum
essential medium with Earle’s salts (EMEM) with supplem ents
as previously described (L. Xu et al., 1997).
Plasmids
The Escherichia coli lacZ gene, driven by a simian virus 40
(SV40) promoter in expression plasm id pSVb, and the firefly
luciferase gene driven by the cytomegalovirus  (CMV) promoter
in plasm id pCMVLuc, were employed as reporter genes (both
from Promega, Madison, WI). The p53 expression plasmid
pCMVp53 contains the 1.7-kb human wt p53 cDNA under the
control of the CMV promoter, followed by the SV40 polyadeny-
lation signal. The control plasmid pCMVpRo contains the same
p53 cDNA in the reversed orientation, also under the control
of the CMV promoter. All the plasmids were expanded in E.
coli DH5 a and purified with plasmid Mega/Giga kits (Qiagen,
Valencia, CA). The purified plasmids were quantified spec-
trophotometrical ly with A260/A280 values of approxim ately 1.95.
Agarose gel (0.8%) electrophoresis confirmed that . 95% of
the plasmid DNA was supercoiled.
Preparation of transferrin–liposome–DNA complex
Cationic liposomes consisting of 1,2-dioleoyl-3-trimethylam-
moniumpropane (DOTAP) and dioleoylphosphatidylethanolamine
(DOPE) (Avanti Polar Lipids, Alabaster, AL) were prepared as
previously described (L. Xu et al., 1997). The final concentra-
tion of liposomes was 2 m mol/ml. Holo-transferrin  (Tf, iron sat-
urated; from Sigma, St. Louis, MO) was dissolved in pure wa-
ter at 5 mg/ml. The Tf–liposome–DNA complex for in vitro
experiments was prepared as described except that the serum -
free medium EMEM was used instead of Hanks’ balanced salt
solution (HBSS) (L. Xu et al., 1997). The prepared Tf–lipo-
some (designated LipT)–DNA complex was used for in vitro
cell transfection freshly within 1 hr of preparation, although on
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the basis of transfection efficiencies it was found to be stable
for at least 24 hr. Agarose gel electrophoresis was employed to
assess the DNA retardation by complexing with LipT.
Optimization of LipT system by luciferase assay
The LipT system was optimized for JSQ-3 transfection us-
ing the luciferase assay. JSQ-3 cells (5 3 104/well) were plated
in a 24-well tissue culture plate. Twenty-four hours later, the
cells were washed once with EMEM without serum, and 0.3
ml of EMEM without serum or antibiotics was added to each
well. EMEM (0.2 ml) with the Tf–liposome–pCMVLuc
(LipT–Luc) complex containing 1.0 m g of plasmid DNA com-
plexed with different amounts of cationic liposome and trans-
ferrin was added to the cells, usually in triplicate. After a 5-hr
incubation at 37°C and 5% CO2, 0.5 ml of EMEM, supple-
mented with 20% fetal bovine serum  and hydrocortisone (1
m g/ml), was added to each well. Twenty-four hours later, the
cells were washed once with phosphate-buffered  saline (PBS),
lysed with 1 3 reporter lysis buffer (100 m l/well; Promega),
and the expressed luciferase activities were measured with the
luciferase assay system (Promega) on a luminometer (Xu et al.,
1999). A recom binant firefly luciferase (Promega) standard was
used at each measurement so as to convert the luminometer
readings of relative light units (RLU) to the amount of luciferase
equivalent expressed. Protein concentrations of the cell lysates
were measured with a DC protein assay kit (Bio-Rad, Hercules,
CA). The results were expressed as micrograms of luciferase
equivalent per milligram of total protein.
In vitro transfection of JSQ-3 cells by LipT–pSVb
A quantitative b -galactosidase colorim etric assay was em-
ployed as described previously (L. Xu et al., 1997). Purified b -
galactosidase (Boehringer Mannheim, Indianapolis, IN) was
used as standard. The results were expressed as milliunits (mU)
of b -galactosidase equivalent per milligram of total protein. For
histochemical studies of Tf–liposome–pSVb transfection, 60%
confluent JSQ-3 cells in a 24-well tissue culture plate were
transfected for 5 hr with 1.2 m g of pSVb with or without LipT
as described above. After an additional 2 days in culture, the
cells were fixed and stained with 5-bromo-4-chlor o-3-indolyl-
b -D -galactopyranoside  (X-Gal), and transfection efficiency was
calculated as the percentage of blue-stained cells as previously
described (L. Xu et al., 1997, 1999).
Western blot analysis
To determine the DNA-dose response of p53 gene expres-
sion, 2 3 105 JSQ-3 cells/well were plated in a six-well tissue
culture plate. After 24 hr, cells were washed once with EMEM
without serum and antibiotics, transfected with 1 ml of trans-
fection solution containing LipT–p53 or LipT–pRo containing
up to 4 m g of plasmid DNA per 2 3 105 cells, at the ratio of 1
m g of DNA per 10 nmol of liposom e per 15 m g of Tf in EMEM.
Five hours after transfection, 1 ml of EMEM supplem ented with
20% fetal bovine serum (FBS) and hydrocortisone (1 m g/ml)
was added and cultured for an additional 48 hr. The transfected
cells were collected and lysed in RIPA radioimmunop recipita-
tion assay buffer (Santa Cruz Biotechnology, Santa Cruz, CA)
and Western blot analysis was performed as previously de-
scribed (L. Xu et al., 1997, 1999). For the time course of p53
gene expression, 2 3 105 JSQ-3 cells were transfected with 2 m g
of pCMVp53 or pCMVpRo complexed with LipT. The cells were
collected for Western blot analysis every 24 hr up to 5 days af-
ter transfection and applied. To analyze the radiation effect on
p53 gene expression, JSQ-3 cells were transfected with
LipT–p53, or LipT–pRo (2 m g of DNA per 2 3 105 cells per
well in a six-well plate) for 2 days, then trypsinized and irradi-
ated in suspension with graded doses (up to 6 Gy) of 137Cs g
rays in a J.L. Shepard and Associates Mark I irradiator (L. Xu et
al., 1997). The irradiated cells were replated and cultured for 2
or 4 days before being harvested for Western blot analysis.
p53 and radiation-indu ced apoptosis
To study p53-induced apoptosis, JSQ-3 cells were trans-
fected with LipT–p53 or LipT–pRo (1 to 3 m g of DNA per 2 3
105 cells) as described above, and both the attached and float-
ing cells were collected every day for 3 days for apoptosis stain-
ing. For radiation-induced  apoptosis, the cells were transfected
for 2 days, and then trypsinized and irradiated as described
above. The replated cells were collected 4 days later for apop-
tosis staining. The collected cells were stained with the annexin
V–fluorescein isothiocyanate (FITC) kit (Trevigen, Gaithers-
burg, MD) according to the manufacturer’ s protocol. The
stained cells were analyzed on a flow cytometer (FACStar; Bec-
ton Dickinson, Franklin Lakes, NJ).
In vivo gene transfection in nude mouse JSQ-3
xenograft model by intravenous injection of
LipT–pSVb
The transferrin– liposome, liposome–pSVb, and pSVb DNA
complexes were prepared as previously described (L. Xu et al.,
1997) at a ratio of 1 m g of DNA per 10 nmol of liposome per
12.5 m g of transferrin. However, sterile 5% dextrose was used
in place of HBSS. The nude mouse tumor model was estab-
lished by subcutaneous injection of 2.5 3 106 JSQ-3 cells in
the flank of 4- to 6-week-old female athym ic nude mice (NCR
nu/nu). pSVb DNA (30 m g) complexed with Tf–liposome in a
300- m l total volume was injected into each mouse via the tail
vein, using a 1-m1 syringe and a 30-gauge needle. In the con-
trol groups, either liposome–pSVb or pSVb DNA without li-
posome was injected. Two and 10 days after DNA injection,
the tumors as well as mouse organs were excised, cut into 1-
mm-thick slices, washed once with PBS, and fixed with 2%
formaldehyde– 0.2% glutaraldehyde for 4 hr at room tempera-
ture. The fixed tumor slices were washed four times with PBS,
each for 1 hr, and stained with X-Gal solution plus 0.1% Non-
idet P-40 (NP-40) (pH adjusted to 8.5) at 37°C overnight. The
stained tumor slices were embedded and sectioned by normal
histological procedures and counterstained with nuclear fast red.
Four sections per tumor were examined to evaluate the b -galac-
tosidase gene expression, as indicated by the blue-stained cells.
In vivo systemic p53 gene therapy in combination 
with radiation
JSQ-3 cells (2.5 3 106) were injected subcutaneously into
the lower back above the tail of athymic NCR nu/nu nude mice.
Seven to 10 days later, the tumors grew to approximately 40–50
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mm3 at the injection site. Freshly prepared LipT–p53 or
LipT–pRo containing 8 m g of DNA in 300 m l of 5% dextrose
was intravenously injected per mouse via the tail vein twice a
week for a total of five injections. Forty-eight hours after the
initial intravenous injection, the animals were secured in a lead
restraint that permitted only the tumor area to be exposed to g
irradiation, and the first fractionated dose of 2.5 Gy of 137Cs
ionizing radiation was administered. Thereafter, the animals
were given 2.5 Gy every 48 hr to a total dose of 25 Gy. For
comparison, a group of untransfected mice, as well as a group
of mice injected with LipT–p53, received no radiation. The tu-
mor sizes were measured weekly in a blinded manner by a third
party at the Georgetown University Animal Facility. All ani-
mal experim ents were performed in accordance with George-
town University institutional guidelines for the care and use of
animals.
Histological analysis of JSQ-3 xenografts after
combination treatment
Subcutaneous JSQ-3 tumors were excised from the animals
at various times after the end of the treatment. The tumor tis-
sues were formalin fixed, sectioned, and stained with H&E ac-
cording to common histological procedure.
Statistical analysis
The Student t test and two-way ANOVA was performed with
GraphPad Prism version 3.00 for Windows (GraphPad Soft-
ware, San Diego, CA; www.graphpad.com).
RESULTS
Optimization of transferrin–liposomes for transfection
of head and neck cancer cells
LipT, the liposome complex based on cationic lipids DOTAP
and DOPE with transferrin, was prepared as previously de-
scribed (L. Xu et al., 1997). To optimize the transfection effi-
ciency, a plasmid designated as pCMVLuc that contains the
firefly luciferase gene driven by the cytomegaloviru s (CMV)
promoter was employed as reporter gene. JSQ-3 cells were
transfected with different DNA–lipid–Tf ratios of LipT-
pCMVLuc (LipT–Luc). Figure 1 shows that transferrin signif-
icantly enhanced the transfection efficiency of cationic lipo-
somes. Under optimal conditions, i.e., a DNA:lipid:Tf ratio of
1 m g:10 nmol:12.5 m g, luciferase was expressed at 12.5 6 1.1
m g/mg total protein, representing 1.25% total protein, 7- to 10-
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FIG. 1. Optimization of transferrin– liposome system by luciferase assay. In a representative experiment, 5 3 104 JSQ-3 cells
per well in a 24-well plate were transfected with Tf–liposome–pCMVLuc (LipT–Luc), containing 1.0 m g of plasmid DNA com-
plexed with various amounts of cationic liposom e and transferrin. Twenty-four hours later, the cells were lysed and the expressed
luciferase activities were measured with the luciferase assay system, with a recom binant firefly luciferase to convert the lumi-
nometer readings of relative light units (RLU) to the amount of luciferase equivalent expressed. The results were expressed as
micrograms of luciferase equivalent per milligram of total protein. The DNA:lipid:Tf ratio of 1 m g:10 nmol:12.5 m g gave the
best transgene expression: 12.5 6 1.1 m g/mg total protein, or 1.25%  total protein.
fold more than liposome alone without transferrin. The results
agreed with our previous report (L. Xu et al., 1997). This ratio
was used as a basic ratio for in vivo optimization below.
In the quantitative b -galactosidase assay, the JSQ-3 cells
transfected under the optimal conditions, with 0.5 m g of DNA
per 105 cells of LipT–pSVb, expressed 15.04 6 0.60 mU/mg
total protein of b -galactosidase without serum, and 10.95 6
0.15 mU/mg in the presence of serum. In histochemical stud-
ies, transfection with LipT–pSVb resulted in 70–80% of the
cells being transfected (see Table 1). The presence of serum
during transfection slightly reduced transfection efficiency, but
even with serum, 40–50% of the cells stained blue, while
cationic liposome without ligand gave only 10–20% transfec-
tion efficiency. These results demonstrated that using Tf as a
ligand significantly increased the transfection efficiency of
cationic liposomes, even in the presence of serum.
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TABLE 1. IN VITRO TRAN SFEC TIO N
EFFIC IEN CIES FOR JSQ-3 CELLS a
Transfection efficiency (%)
Transfected with: Without serum With serum
pSVb alone 0 0
Lip–pSVb 20 , 10
LipT–pSVb 70–80 40–50
aJSQ-3 cells (60% confluent), cultured in a 24-well plate,
were transfected for 5 hr with 0.5 ml of transfection solution
containing 1.2 m g of pSVb. After an additional 2 days in cul-
ture, the cells were fixed and stained with X-Gal. Transfection
efficiency was calculated as the percentage of blue-stained cells.
LipT–pSVb, transferrin– liposome–pSVb complex; Lip-pSVb,
liposome–pSVb without transferrin.
FIG. 2. Expression of exogenous wt p53 protein in LipT–p53-transfected JSQ-3 cells in vitro and its relationship to radiation.
UT, Untransfected JSQ-3 cells; Lip T–p53, cells transfected with transferrin– liposom e complexed to p53 plasm id pCMVp53;
LipT–pRo, transferrin– liposome complexed to pCMV-pRo, the plasmid containing p53 gene in the reverse orientation. The ar-
rows indicate exogenous wt p53. (A) DNA dose response of LipT–p53 transfection. JSQ-3 cells were transfected in a six-well
plate for 5 hr with increasing amounts of LipT–p53 or LipT–pRo as described in Materials and Methods. Forty-eight hours later
the cells were collected and lysed for Western blot. A total of 40 m g of protein was loaded per lane. (B) Time course of exoge-
nous wt p53 expression in JSQ-3 cells. The cells were transfected with LipT–p53 or LipT–pRo at 2 m g of plasm ic DNA per 2 3
105 cells. At the indicated time, the cells were collected and lysed for Western blot analysis as described above. (C) Effect of g
irradiation on wt p53 gene expression JSQ-3 cells were transfected with LipT–p53 or LipT–pRo (2 m g of DNA per 2 3 105 cells)
for 2 days, then trypsinized and irradiated at graded doses up to 6 Gy of 137Cs g rays. The irradiated cells were replated and cul-
tured for a further 2 and 4 days before collecting for Western blot analysis. The g irradiation can enhance and/or stabilize the ex-
ogenous wt p53 expression in a radiation dose-dependent manner.
Expression of exogenous wild-type p53 protein in
LipT–p53-transfected JSQ-3 cells
Western blot analysis was employed to demonstrate that the
LipT-transduc ed wt p53 was being expressed in JSQ-3 cells.
As shown in Fig. 2A, transfection with increasing doses of p53
expression plasmid pCMVp53 complexed with LipT
(LipT–p53) resulted in a DNA dose-dependent expression of
wt p53, while no exogenous p53 expression was evident in JSQ-
3 cells transfected with LipT–pRo, which carries the wt p53
cDNA in reverse orientation. Wild-type p53 was expressed 24
hr after LipT–p53 transfection and peaked on the second day
(Fig. 2B). Only traces of exogenous p53 were detected 5 days
after transfection, indicating that LipT-mediated wt p53 ex-
pression was transient (Fig. 2B). When the cells were irradi-
ated 48 hr after LipT–p53 transfection, i.e., at the peak of ex-
ogenous wt p53 expression, the level of wt p53 protein
increased with increasing doses of g irradiation (Fig. 2C). The
level of p53 protein still present even 4 days postirradiation
(i.e., 6 days posttransfection) indicates that g irradiation can en-
hance and/or stabilize the exogenous wt p53 expression in a ra-
diation dose-dependent manner, analogous to the situation ob-
served in cells with naturally occurring wt p53.
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Apoptosis induced by p53 transfection and 
g irradiation
To examine the effect of wt p53 restoration on the induction
of apoptosis, JSQ-3 cells were transfected with LipT–p53 or
LipT–pRo, then stained on days 1 to 3 with annexin V–FITC,
which binds specifically to phosphatidylserine  present on apop-
totic cells. As shown in Fig. 3, a clear induction of apoptosis
is observed with LipT-mediated wt p53 restoration, in a DNA
dose-dependent manner. The percentage of apoptotic cells
peaked on the second day of transfection, correlating with the
levels of wt p53 expression in the cells as revealed by Western
blot (Fig. 2B). To examine the effect of irradiation on the in-
duction of apoptosis, the transfected cells were irradiated with
various doses 48 hr after transfection. Two to 4 days later, the
cells were stained with annexin V–FITC and analyzed by flow
cytometry. As shown in Fig. 4A, g irradiation induced a sig-
nificant increase in apoptosis only in LipT–p53-transfected
cells, from 18.7% (0 Gy) to 38.7% (4 Gy) and 46.4% (6 Gy) 2
days after irradiation (or 4 days after transfection). No increase
was observed with untransfected (UT) cells or those transfected
with LipT or LipT–pRo. This increase was also radiation dose
dependent and correlated, as indicated in Fig. 4B, with the wt
FIG. 3. LipT–p53 transfection-induce d apoptosis. JSQ-3 cells were transfected with LipT–p53 or LipT–pRo, then stained from
day 1 to day 3 with annexin V–FITC, which bound specifically to phosphatidylserin e present on apoptotic cells. A clear induc-
tion of apoptosis is observed in LipT-mediated wt p53 restoration, in a DNA dose-dependent manner.
p53 expression levels shown in Fig. 2C (r 5 0.9843), demon-
strating that the radiation enhancement of apoptosis was pro-
portional to the wt p53 level in cells, i.e., the more wt p53 ex-
pressed, the more apoptotic cells induced.
In vivo transfection of systemically delivered
LipT–pSVb complex
To examine the ability of the Tf-containing liposomes to se-
lectively target tumor tissue in vivo , LipT–pSVb or the pSVb
plasmid alone was injected intravenously into nude mice bear-
ing JSQ-3 subcutaneous xenografts. After either 2 or 10 days,
the tumors and major organs were examined by histochemical
staining with X-Gal. At 2 days, the tumors in mice injected with
LipT–pSVb showed reporter gene expression representing an
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FIG. 4. The effect of irradiation on the induction of apoptosis. (A) The transfected cells were irradiated at various doses 48 hr
after transfection. Two to 4 days later, the cells were stained with annexin V–FITC and analyzed by flow cytometry. g Irradia-
tion induced a significant increase in apoptosis only of LipT–p53-transfected cells. (B) The increase was radiation dose depen-
dent and correlated with the wt p53 expression levels from Western blot data.
in vivo transfection efficiency of approximately 20–30% with
one intravenous injection (Color Plate 1A and B). In contrast,
with pSVb plasmid alone, without liposome, less than 1% of
the tumor cells stained for reporter gene expression (Color Plate
1D). Ten days after intravenous administration of LipT–pSVb,
both the percentage of positive cells and the intensity of blue
staining in the tumors were significantly reduced (Color Plate
1C), indicating that the LipT-mediated systemic transfection
was transient. Vital organs in mice injected with LipT–pSVb
showed staining only of macrophages, such as histocytes of the
lung (Color Plate 1E) or Kupffer cells of the liver (Color Plate
1F), whereas the lung alveolar cells and hepatocytes remained
unstained. No staining was evident in the lymphoblastic growth
centers in the spleen (data not shown). In summary, the histo-
chemical staining indicates that delivery of the reporter gene by
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FIG. 5. Effect of the combination of LipT–p53 and radiation treatment on JSQ-3 xenografts in vivo. Day 0 represents the tu-
mor volum e prior to initiation of treatment. The last point represents 81 days (A) or 195 days (B) posttreatment. While there was
no significant difference between the three control groups, the difference between the controls and the combination LipT–p53-
treated group was highly significant. The standard error for the combination group was negligible. The bar indicates the dura-
tion of treatment (a total of five intravenous LipT injections and 25 Gy of radiation).
A
B
Color Plate 1. In vivo LipT-mediated system ic transfection of b -galactosidase reporter gene in nude mouse JSQ-3 xenografts.
The b -galactosidase-ex pressing cells stained blue. (A) JSQ-3 xenograft tumor from a mouse injected intravenously with
LipT–pSVb, 48 hr postinjection; (B) second, independent xenograft tumor from a mouse injected intravenously with LipT–pSVb,
48 hr postinjection; (C) JSQ-3 tumor treated intravenously with LipT–pSVb, 10 days after injection; (D) tumor from mouse in-
jected intravenously with pSVb alone, 48 hr postinjection; (E) lung from a mouse carrying a JSQ-3 xenograft tumor and injected
intravenously with LipT–pSVb, 48 hr postinjection; (F) liver from a mouse carrying a JSQ-3 xenograft tumor and injected in-
travenously with LipT–pSVb. Bars: 50 m m.
Color Plate 2. Histological analysis of JSQ-3 xenografts after combination treatment Subcutaneous JSQ-3 tumors were excised
from the animals at various times after and the end of treatment with radiation and/or intravenously administered LipT–p53 or
LipT–pRo. The mass was formalin fixed, sectioned, and stained with H&E. Shown is tumor or residual mass from animals that
received (A) LipT–p53 plus 25 Gy, 1 day posttreatment; (B) LipT–pRo plus 25 Gy, 1 day posttreatment; (C) no intravenous
treatment but 25 Gy of radiation, 1 day posttreatment; (D) LipT–p53 plus 25 Gy, 1 month posttreatment; (E and G) LipT–p53
plus 25 Gy (two individual tumors), 6 months posttreatment; (F) enlargement of the area indicated in (E), showing dead tumor
cells being engulfed by Langerhans cells; (H) LipT–p53, without radiation treatment, 6 months posttreatment; (I) LipT–pRo plus
25 Gy, 6 months posttreatm ent. m, Normal muscle. Bars: 50 m m.
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Color Plate 1
Color Plate 2
LipT is selective, with the human xenograft being most heav-
ily stained.
Effect of the combination  of LipT–p53 and radiation
treatment on JSQ-3 xenografts in vivo
Two independen t experimen ts with SCCHN (JSQ-3)
xenograft tumors have been performed  with similar results
(Fig. 5A and B). Mice bearing subcutaneou s JSQ-3 tumors of
approxim ately 25–40 mm3 were injected, via the tail vein, with
LipT–p53 twice weekly (a total of five injections)  and only
the tumor areas were exposed to fractionate d doses (2.5 Gy)
of g radiation, every other day to a total of 25 Gy. As shown
in Fig. 5A and B, short-term  radiation effects on tumor growth
were evident in cells transfected using the control LipT–pRo.
There was only minimal tumor growth inhibition in the ani-
mals that received LipT–p53 without radiation. In contrast, in
both experiment s all the tumors that received the combinatio n
of LipT–p53 plus radiation exhibited virtually complete re-
gression and showed no signs of recurrence (p , 0.001). In
the case of the longer maintained experiment  (Fig. 5B), the
tumor-bear ing animals in control groups had died or were hu-
manely euthanized because of excessive tumor burden by 6
months postirradiat ion. However, the combinatio n treatment
group (p53 plus irrdiation) still showed no sign of tumor re-
growth (Fig. 5B).
Histology of the small residual “tumor nodule”  present in
some of the animals, which was static at less than 10% of the
original tumor volum e over the entire course of the experi-
ment, is shown in Color Plate 2. In the mice that had received
LipT–p53 plus radiation, it is evident that mostly dead and
dying tumor cells, many being engulfed by macrophages,  and
few live tumor cells remain 1 day after completion of treat-
ment (Color Plate 2A). In contrast, although radiation effects
are evident, live nests of tumor cells are clearly visible in the
mice that received LipT–pRo plus radiation (Color Plate 2B).
For comparison, an untreated tumor receiving radiation alone
is shown in Color Plate 2C. Color Plate 2D shows, 1 month
posttreatm ent, residual tissue at the site of the original tumor
in an animal that received LipT–p53 plus radiation. No live
tumor cells were evident; only scar tissue and a few multin-
uclear Langerhan s cells were present. By 6 months posttreat-
ment, only mature scar tissue and numerous macrophag es or
Langerhan s cells in the process of surroundin g and engulfing
the remains of the dead tumor cells, are evident in the resid-
ual tumor mass from the animal in the combination treatment
group (Color Plate 2E and G). An enlargem ent of this is shown
in Color Plate 2F. In contrast, large areas of live cancer cells
can be seen in the tumor from an animal receiving LipT–p53
without radiation (Color Plate 2H) or LipT–pRo plus radia-
tion (Color Plate 2I). These observation s were confirm ed by
an experienced  pathologist  and are consistent with our previ-
ous results in studies with intratum orally injected, adenoviral
vector carrying wt p53 in conjunction  with radiation (Pirollo
et al., 1997). These experim ents using a mouse cancer model
demonstrate that the combination of transferrin- targeted sys-
temic liposomal p53 gene therapy and conventiona l radio-
therapy was markedly more effective than either treatment
alone.
DISCUSSION
The development of viral and nonviral methods for the in-
troduction of genes into cells in vivo has made therapeutic in-
terventions involving gene therapy a reality. The introduction
of wt p53 has been reported to suppress the growth of various
types of malignancies, both in vitro and in mouse xenograft
models. However, most of the in vivo results are obtained with
viral p53 gene vectors and local administration (Fujiwara et al.,
1994; Clayman et al., 1995; Liu et al., 1995; reviewed by Niel-
son and Maneval, 1998). To overcome the limitations of the vi-
ral vectors, including the immunogenici ty and biosafety issues,
and to realize the ultimate goal of systemic cancer gene ther-
apy, nonviral gene delivery, especially ligand-directed tumor-
targeted system ic gene delivery, is an attractive alternative.
We have previously reported that wt p53 replacem ent by a
nonviral gene delivery system, transferrin– liposome–DNA
complex, sensitized SCCHN cells to radiation in vitro (L. Xu
et al., 1997). This system was further optimized for systemic
gene delivery in vivo. The results described above demonstrate
that the transferrin– cationic liposome system can deliver genes
systemically to xenograft tumors in vivo , after intravenous ad-
ministration. Twenty to 30% in vivo transfection efficiency was
achieved via intravenous injection of the LipT–DNA complex.
The LipT-mediated p53 gene transfer apparently restored a
functional apoptotic pathway in the SCCHN cells, thereby sen-
sitizing the tumors to radiation therapy. Total tumor regression
was observed in a nude mouse xenograft model of human 
SCCHN by a systemically delivered nonviral p53 vector in
combination with conventional radiation therapy. The combi-
nation of systemic LipT–p53 gene therapy and radiotherapy for
SCCHN was markedly more effective than either treatment
alone. This observation is consistent with our report of ra-
diosensitization by folate–liposome-m ediated p53 gene therapy
(Xu et al., 1999). Although systemic LipT–p53 alone showed
suppressive effects on tumor growth, as observed here and also
by others (Lesoon-Woo et al., 1995; M. Xu et al., 1997), the
tumor would ultimately recur after the treatment ceased. How-
ever, when LipT–p53 was combined with conventional radio-
therapy, the established tumors regressed for up to 6 months
after the end of treatment without recurrence. In the small resid-
ual “tumor nodules”  that were static at less than 10% of the
original tumor volume, only scar tissue and numerous macro-
phages or multinuclear Langerhans cells, in the process of sur-
rounding and engulfing the remains of the dead tumor cells,
were observed. Therefore, host macrophages might be involved
in the treatment response (discussed below).
Lack of functional p53 results in the inability of the tumor
cell to initiate programmed cell death (apoptosis) in response
to DNA damage induced by radiation or other agents. Re-
placement of wild-type p53 should therefore restore the apop-
totic response to irradiation (Liu et al., 1995). We have demon-
strated previously that adenovirus mediated restoration of wt
p53, in combination with radiation treatment, was able not only
to inhibit tumor growth, but also to completely eliminate es-
tablished radiation-resistant SCCHN xenograft tumors (Pirollo
et al., 1997). This adenoviral wt p53 replacement also restored
the G1 checkpoint and the g radiation-induced apoptotic path-
way in the tumor cells, and therefore sensitized the tumors to
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radiotherapy (Chang et al., 1997). The results presented here
demonstrate that (1) transferrin– liposome-medi ated p53 gene
delivery can efficiently restore wt p53 function and the apop-
totic pathway; (2) g irradiation can enhance and/or stabilize 
exogenous wt p53 expression in a radiation dose-dependent
manner; (3) radiation induces a significant increase in p53-de-
pendent apoptosis; and (4) this increase is radiation dose de-
pendent and correlates with the exogenous wt p53 level in tu-
mor cells. Further work is now underway to analyze the
LipT–p53-m ediated changes in p53 downstream effectors or re-
lated molecules, e.g., p21 WAF1, Bcl-2, MDM2, p19ARF, etc.,
as well as cell cycle-related analysis.
The host defense system plays as important role in interac-
tions between therapeutic regimens and target tissue, especially
in the case of cancer gene therapy. With transferrin-targeted
cationic liposome gene delivery, although only a fraction of tu-
mor cells were transfected, the combination therapy resulted in
tumor regression without recurrence 6 months after the treat-
ment stopped. Antiangiogenesi s may be an important mecha-
nism involved in the system, as observed by M. Xu et al. (1997).
Liu et al. (1999) reported that system ic p53 gene delivery by
cationic liposome inhibited angiogenesis by inducing endoge-
nous thrombospondin -1 expression. Natural killer (NK) cells,
which are abundant in the nude mouse, may also play a role in
the tumor regression, as suggested by Hall et al. (1998). As
mentioned above, host macrophages are involved in the tumor
response. Systemic LipT–p53 gene therapy plus radiation re-
sulted in tumor cell death, likely through the induction of apop-
tosis. These apoptotic cells were phagocytosed by macrophages
and possibly also by dendritic cells. The macrophages and den-
dritic cells can then serve as antigen-presenting  cells to stimu-
late the host immune system (Lotze and Jaffe, 1999). In the
case of the athym ic nude mouse, which lacks T lymphocytes,
NK cells may be involved. Peron et al. (1999) suggested a den-
dritic cell–NK cell link, in antitum or therapy. Currently, we are
testing LipT–p53 systemic gene therapy in immune-com petent
syngenic tumor models to explore the immunologica l and mol-
ecular mechanisms.
In conclusion,  the transferrin– liposom e system is a highly
efficient and tumor-specific gene delivery system both in vitro
and in vivo . The replacem ent of wild-type p53 by LipT–p53
restored the wt p53 functional apoptotic pathway. The sys-
temic delivery of LipT–p53 to established human SCCHN
xenografts markedly sensitized the tumors to radiation ther-
apy. The combinatio n of system ic p53 gene therapy and con-
ventional radiotherap y resulted in tumor regression and inhi-
bition of their recurrence long-term . This strategy may provide
a more effective treatment modality for human head and neck
cancer.
ACKNOWLEDGMENTS
We thank Ms. Tina Wilson for assistance with the in vivo
animal studies, Dr. Laiman Xiang for assistance with tissue cul-
ture, Drs. Karen Creswell and Wen-Hui Zhu for assistance with
flow cytometery analysis, and Dr. Williams Alexander for his
critical review  of the manuscript. This work was supported in
part by NCI Grant R01 CA 45158 (E.C.) and Synergene Ther-
apeutics, Inc.
REFERENCES
BATES, S., and VOUSDEN, K.H. (1999). Mechanisms of p53-medi-
ated apoptosis. Cell. Mol. Life Sci. 55, 28–37.
BRISTOW, R.G., BENCHIMOL, S., and HILL, R.P. (1996). The p53
gene as a modifier of intrinsic radiosensitivity: implications for ra-
diotherapy. Radiother. Oncol. 40, 197–223.
CHACKAL-ROY, M., NIEMEYER, C., MOORE, M., and ZETTER,
B.R. (1989). Stimulation of human prostatic carcinoma cell growth
by factors present in human bone marrow. J. Clin. Invest. 84, 43–50.
CHANG, E.H., JANG, Y.J., HAO, Z., MURPHY, G., RAIT, A., FEE,
W.E., Jr., SUSSMAN, H.H., RYAN, P., CHIANG, Y., and
PIROLLO, K.F. (1997). Restoration of the G1 checkpoint and the
apoptotic pathway mediated by wild-type p53 sensitizes squamous
cell carcinoma of the head and neck to radiotherapy. Arch. Oto-
laryngol. Head Neck Surg. 123, 507–512.
CHENG, P.W. (1996). Receptor ligand-facilitated  gene transfer: En-
hancement of liposome-med iated gene transfer and expression by
transferrin. Hum. Gene Ther. 7, 275–282.
CHRISTIANO, R.J., and CURIEL, D.T. (1996). Strategies to accom-
plish gene therapy via the receptor-mediated endocytosis pathways.
Cancer Gene Ther. 3, 457–497.
CLAYMAN, G.L., EL-NAGGAR, A.K., ROTH, J.A., ZHANG, W.W.,
GOEPFERT, H., TAYLOR, D.L., and LIU, T.J. (1995). In vivo mol-
ecular therapy with p53 adenovirus for microscopic residual head
and neck squamous carcinoma. Cancer Res. 55, 1–6.
DIMERY, I.W., and HONG, W.K. (1993). Overview of combined
modality therapies for head and neck cancer. J. Natl. Cancer Inst. 85,
95–111.
ELLIOTT, R.L., ELLIOTT, M.C., WANG, F., and HEAD, J.F. (1993).
Breast carcinoma and the role of iron metabolism. A cytochemical,
tissue culture, and ultrastructural study. Ann. N.Y. Acad. Sci. 698,
159–166.
FELGNER, P.L., TSAI, Y.J., SUKHU, L., WHEELER, C.J., MAN-
THORPE, M., and MARSHALL, J. (1995). Improved cationic lipid
formulations for in vivo gene therapy. Ann. N.Y. Acad. Sci. 772,
126–139.
FUJIWARA, T., GRIMM, E.A., MUKHOPADHYAY, T., ZHANG,
W.W., OWEN-SCHAUB, L.B., and ROTH, J.A. (1994). Induction
of chemosensitivity  in human lung cancer cells in vivo by adenovirus-
mediated transfer of the wild-type p53 gene. Cancer Res. 54,
2287–2291.
GRAYHACK, J.T., WENDEL, E.F., OLIVER, L., and LEE, C. (1979).
Analysis of specific proteins in prostatic fluid for detecting prosta-
tic malignancy. J. Urol. 121, 295–299.
HALL, S.J., SANFORD, M.A., ATKINSON, G., and CHEN, S.H. (1998).
Induction of potent antitumor natural killer cell activity by herpes sim-
plex virus-thymidine  kinase and ganciclovir therapy in an orthotopic
mouse model of prostate cancer. Cancer Res. 58, 3221–3225.
HUANG, L., and VIROONCHATAPAN, E. (1990). Introduction. In
Non-Viral Vectors for Gene Therapy . L. Huang, M.C. Hung, and E.
Wagner, eds. (Academic Press, San Diego, CA) pp. 3–22.
INOUE, T., CAVANAUGH, P.G., STECK, P.A., BRUNNER, N., and
NICOLSON, G.L. (1993). Differences in transferrin response and
numbers of transferrin receptors in rat and human mammary carci-
noma lines of different metastatic potentials. J. Cell Physiol. 156,
212–217.
KEER, H.N., KOZLOWSKI, J.M., and TSAI, M.C. (1990). Elevated
transferrin receptor content in human prostate cancer cell lines as-
sessed in vitro and in vivo. J. Urol. 143, 381–385.
LANDIS, S.H., MURRAY, T., BOLDEN, S., and WINGO, P.A.
(1998). Cancer statistics, 1998. CA Cancer J. Clin. 48, 6–29.
LEE, J.M., and BERNSTEIN, A. (1993). p53 mutations increase re-
sistance to ionizing radiation. Proc. Natl. Acad. Sci. U.S.A. 90,
5742–5746.
SYSTEMIC p53 GENE THERAPY OF CANCER 2951
LESOON-WOOD, L.A., HO KIM, W., KLEINMAN, H.R., WEIN-
TRAUB, B.D., and MIXSON, A.J. (1995). Systemic gene therapy
with p53 reduces growth and metastases of a malignant human breast
cancer in nude mice. Hum. Gene Ther. 6, 395–405.
LIU, T.J., EL-NAGGAR, A.K., MCDONNELL, T.J., STECK, K.D.,
WANG, M., and TAYLOR, D.L. (1995). Apoptosis induction me-
diated by wild-type p53 adenoviral gene transfer in squamous cell
carcinoma of the head and neck. Cancer Res. 55, 3117–3122.
LIU, Y., THOR, A., SHTIVELMAN, E., CAO, Y., TU, G., HEATH,
T.D., and DEBS, R.J. (1999). Systemic gene delivery expands the
repertoire of effective antiangiogenic agents. J. Biol. Chem. 274,
13338–13344.
LOTZE, M.T., and JAFFE, R. (1999). Dendritic cells in disease: Can-
cer. In Dendritic Cells: Biology and Clinical Applications . M.T.
Lotze and A.W. Thomson, eds. (Academic Press, San Diego, CA)
pp. 325–338.
MCILWRATH, A.J., VASEY, P.A., ROSS, G.M., and BROWN, R.
(1994). Cell cycle arrests and radiosensitivity of human tumor cell
lines: dependence on wild-type p53 for radiosensitivity. Cancer Res.
54, 3718–3722.
MENG, R.D., and EL-DEIRY, W.S. (1999). Tumor suppressor genes
as targets for cancer gene therapy. In Gene Therapy of Cancer . E.C.
Lattime and S.L. Gerson, eds. (Academic Press, San Diego, CA), pp.
3–20.
MIYAMOTO, T., TANAKA, N., EISHI, Y., and AMAGASA, T.
(1994). Transferrin receptor in oral tumors. Int. J. Oral Maxillofac.
Surg. (Denmark) 23, 430–433.
NIELSON, L.L., and MANEVAL, D.C. (1998). p53 tumor suppressor
gene therapy for cancer. Cancer Gene Ther. 5, 52–63.
O’CONNOR, P.M., JACJMAN, J., JONDLE, D., BHATIA, K., MA-
GRATH, I., and KOHN, K.W. (1993). Role of the p53 tumor sup-
pressor gene in cell cycle arrest and radiosensitivity of Burkitt’s lym-
phoma cell lines. Cancer Res. 53, 4776–4780.
PERON, J.M., ESCHE, C., SUBBOTIN, V.M., MALISZEWSKI, C.,
LOTZE, M.T., and SHURIN, M.R. (1998). FLT3-ligand adminis-
tration inhibits liver metastases: Role of NK cells. J. Immunol. 161,
6164–6170.
PIROLLO, K.F., HAO, Z., RAIT, A., JANG, Y.J., FEE, W.E., Jr.,
RYAN, P., CHIANG, Y., and CHANG, E.H. (1997). p53 mediated
sensitization of squamous cell carcinoma of the head and neck to ra-
diotherapy. Oncogene 14, 1735–1746.
ROSSI, M.C., and ZETTER, B.R. (1992). Selective stimulation of pro-
static carcinoma cell proliferation by transferrin. Proc. Natl. Acad.
Sci. U.S.A. 89, 6197–6201.
ROTH, J.A. (1998). Restoration of tumour suppressor gene expression
for cancer. Forum (Genova) 8, 368–376.
RULEY, H.E. (1996). p53 and response to chemotherapy and radio-
therapy. In Important Advances in Oncology 1996 . V.T. DeVita, S.
Hellman, and S.A. Rosenberg, eds. (Lippincott-Rave n, Philadelphia,
PA), pp. 37–56.
TEMPLETON, N.S., LASIC, D.D., FREDERIK, P.M., STREY, H.H.,
ROBERTS, D.D., and PAVLAKIS, G.N. (1997). Improved DNA:li-
posome complexes for increased systemic delivery and gene ex-
pression. Nature Biotechnol. 15, 647–652.
THORSTENSEN, K., and ROMSLO, I. (1993). The transferrin recep-
tor: Its diagnostic value and its potential as therapeutic target. Scand.
J. Clin. Lab. Invest. Suppl. 215, 113–120.
VAN DONGEN, G.A., and SNOW, G.B. (1997). Prospects for future
studies in head and neck cancer. Eur. J. Surg. Oncol. 23, 486–491.
[UNREF1WAGNER, E. (1999). Ligand–polycation conjugates for re-
ceptor-targeted  gene transfer. In Non-Viral Vectors for Gene Ther-
apy. L. Huang, M.C. Hung, and E. Wagner, eds. (Academic Press,
San Diego, CA) pp. 208–227.
WEICHSELBAUM, R.R., BECKETT, M.A., VOKES, E.E., HALLA-
HAN, D.E., HARAF, D.J., and BRACHMAN, D.G. (1993). Cellu-
lar and molecular basis for radioresistance  in head and neck cancer.
Head Neck Cancer III, 399–407.
XU, L., PIROLLO, K.F., and CHANG, E.H. (1997). Transferrin–lipo-
some-mediated p53 sensitization of squamous cell carcinoma of the
head and neck to radiation in vitro . Hum. Gene Ther. 8, 467–475.
XU, L., PIROLLO, K.F., RAIT, A., MURRAY, A.L., and CHANG,
E.H. (1990). Systemic p53 gene therapy in combinat ion with ra-
diation results in human tumor regression. Tumor Targeting  4,
92–104.
XU, M., KUMAR, D., SRINIVAS, S., DETOLLA, L.J., YU, S.F.,
STASS, S.A., and MIXSON, A.J. (1997). Parenteral gene therapy
with p53 inhibits human breast tumors in vivo through a bystander
mechanism without evidence of toxicity. Hum. Gene Ther. 8,
177–185.
Address reprint requests to:
Dr. Esther H. Chang
Lombardi Cancer Center
The Research Building/E420
Georgetown University Medical Center
3970 Reservoir Road NW
Washington, D.C. 20007
E-mail: change@ gunet.georgetow n.edu
Received for publication July 20, 1999; accepted after revision
September 20, 1999.
XU ET AL.2952
